Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Thursday announced the availability of its US Food and Drug Administration (FDA) approved Cinacalcet Tablets in the United States.
Dr. Reddy's Cinacalcet Tablets are a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets. The Sensipar brand and generic market had US sales of approximately USD312m MAT for the 12 months ending in July 2020, according to IQVIA Health.
Cinacalcet Tablets are available in 30 mg, 60 mg and 90 mg tablets in a bottle count size of 30.
Cinacalcet is a medication used to treat secondary hyperparathyroidism, parathyroid carcinoma and primary hyperparathyroidism.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream